
In patients with ovarian cancer (OC) undergoing platinum‐based chemotherapy and PARP‐inhibitor treatment, BRCA1 deficiency is used as major predictive marker for estimating response to therapy. Here, we present a highly sensitive and specific liquid biopsy assay that assesses BRCA1 gene promoter hypermethylation on circulating tumor DNA (ctDNA) isolated from blood plasma. Our results suggest that hypermethylation and methylation conversion of the BRCA1 promoter in ctDNA are independently correlated to longer progression‐free survival of patients with OC...
Like
Save
Share